Skip to main content
TipRanks
Go Ultimate75% OFF

Bright Minds Biosciences (DRUG) Ratios

300 Followers

Bright Minds Biosciences Ratios

DRUG's free cash flow for Q3 2026 was C$-8.42M. For the 2026 fiscal year, DRUG's free cash flow was increased by C$0.00 and operating cash flow was C$-8.42M. See a summary of the company’s cash flow.

Financial ratios
RatiosSep 25Dec 24Sep 23Sep 22Sep 21
Liquidity Ratios
Current Ratio36.1011.3224.268.1131.38
Quick Ratio36.1011.3224.268.1131.38
Cash Ratio35.5010.8224.037.9030.94
Solvency Ratio-5.11-4.80-25.99-9.830.17
Operating Cash Flow Ratio-3.72-3.50-25.01-9.23-11.46
Short-Term Operating Cash Flow Coverage0.00-23.310.000.000.00
Net Current Asset ValueC$ 81.93MC$ 5.42MC$ 6.53MC$ 10.40MC$ 19.40M
Leverage Ratios
Debt-to-Assets Ratio0.000.020.010.010.00
Debt-to-Equity Ratio0.000.020.010.010.00
Debt-to-Capital Ratio0.000.020.010.010.00
Long-Term Debt-to-Capital Ratio0.000.000.000.000.00
Financial Leverage Ratio1.031.101.041.151.03
Debt Service Coverage Ratio0.00-30.79-368.61-67.100.00
Interest Coverage Ratio0.00-314.57-373.00-66.170.00
Debt to Market Cap0.000.010.000.000.00
Interest Debt Per Share0.020.030.030.150.00
Net Debt to EBITDA6.812.060.920.780.00
Profitability Margins
Gross Profit Margin0.00%0.00%0.00%0.00%0.00%
EBIT Margin0.00%0.00%0.00%0.00%0.00%
EBITDA Margin0.00%0.00%0.00%0.00%0.00%
Operating Profit Margin0.00%0.00%0.00%0.00%0.00%
Pretax Profit Margin0.00%0.00%0.00%0.00%0.00%
Net Profit Margin0.00%0.00%0.00%0.00%0.00%
Continuous Operations Profit Margin0.00%0.00%0.00%0.00%0.00%
Net Income Per EBT100.00%100.00%100.00%101.49%98.43%
EBT Per EBIT87.74%99.58%100.08%101.51%98.77%
Return on Assets (ROA)-14.49%-45.90%-107.17%-125.65%-42.49%
Return on Equity (ROE)-14.91%-50.61%-111.73%-144.06%-43.89%
Return on Capital Employed (ROCE)-16.98%-50.46%-111.65%-138.89%-45.14%
Return on Invested Capital (ROIC)-16.96%-49.07%-110.42%-138.00%-44.44%
Return on Tangible Assets-14.49%-45.90%-107.17%-125.65%-42.50%
Earnings Yield-2.11%-44.22%-92.20%-72.33%-10.50%
Efficiency Ratios
Receivables Turnover0.000.000.000.000.00
Payables Turnover0.000.180.400.000.00
Inventory Turnover0.000.000.000.000.00
Fixed Asset Turnover0.000.000.000.000.00
Asset Turnover0.000.000.000.000.00
Working Capital Turnover Ratio0.000.000.000.000.00
Cash Conversion Cycle0.00-2027.82-918.45-75356.990.00
Days of Sales Outstanding0.000.000.000.000.00
Days of Inventory Outstanding0.000.000.000.000.00
Days of Payables Outstanding0.002027.82918.4575356.990.00
Operating Cycle0.000.000.000.000.00
Cash Flow Ratios
Operating Cash Flow Per Share-1.26-0.43-1.89-5.50-4.08
Free Cash Flow Per Share-1.26-0.43-1.89-5.50-4.08
Dividend Paid and CapEx Coverage Ratio0.00-462546.50-1404853.000.000.00
Capital Expenditure Coverage Ratio0.00-462546.50-1404853.000.000.00
Operating Cash Flow Coverage Ratio-69.10-15.55-95.50-97.110.00
Operating Cash Flow to Sales Ratio0.000.000.000.000.00
Free Cash Flow Yield-1.50%-29.20%-87.85%-64.71%-9.02%
Valuation Ratios
Price-to-Earnings (P/E) Ratio-47.44-2.26-1.08-1.38-9.53
Price-to-Sales (P/S) Ratio0.000.000.000.000.00
Price-to-Book (P/B) Ratio7.081.141.211.994.18
Price-to-Free Cash Flow (P/FCF) Ratio-66.82-3.42-1.14-1.55-11.08
Price-to-Operating Cash Flow Ratio-66.82-3.42-1.14-1.55-11.08
Price-to-Earnings Growth (PEG) Ratio-0.270.030.02-0.05-0.01
Enterprise Value Multiple-40.98-0.27-0.18-0.650.00
Enterprise Value497.97M734.81K1.32M9.51M61.37M
EV to EBITDA-40.98-0.27-0.18-0.650.00
EV to Sales0.000.000.000.000.00
EV to Free Cash Flow-57.29-0.40-0.19-0.70-8.38
EV to Operating Cash Flow-57.29-0.40-0.19-0.70-8.38
Tangible Book Value Per Share11.931.281.774.2710.81
Shareholders’ Equity Per Share11.931.281.774.2710.81
Tax and Other Ratios
Effective Tax Rate0.000.000.00-0.010.02
Revenue Per Share0.000.000.000.000.00
Net Income Per Share-1.78-0.65-1.98-6.15-4.74
Tax Burden1.001.001.001.010.98
Interest Burden1.001.001.001.021.00
Research & Development to Revenue0.000.000.000.000.00
SG&A to Revenue0.000.000.000.000.00
Stock-Based Compensation to Revenue0.000.000.000.000.00
Income Quality0.710.660.950.910.85

Currency in CAD